Furmonertinib is an Oral, Irreversible, Highly BrainPenetrant Pan-EGFR Inhibitor with Activity Against Classical and Atypical EGFR Mutations

被引：0
|
作者：
Musib, L. [1 ]
Kowanetz, M. [1 ]
Li, Q. [2 ]
Luo, H. [2 ]
Hu, J. [2 ]
Lutzker, S. [1 ]
机构：
[1] ArriVent Biopharma, Newtown Sq, PA USA
[2] Allist Pharmaceut, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP01.11
引用
收藏
页码：E14 / E15
页数：2
相关论文
共 30 条
  • [1] Preclinical activity of ORIC-114, a highly selective, brain penetrant, irreversible kinase inhibitor, against atypical mutations in EGFR
    Junttila, M. R.
    Warne, R.
    Repellin, C.
    Sambucetti, L.
    Chang, J.
    Kim, S.
    Kim, H. Y.
    Shin, D. G.
    Park, D. H.
    Patel, R.
    Maneval, E. Chow
    Multani, P. S.
    Daemen, A.
    Friedman, L.
    ANNALS OF ONCOLOGY, 2023, 34
  • [2] Identification of TRE-130 as Reversible Inhibitor of Pan-EGFR Mutants while Sparing EGFR Wild-Type Activity
    Duggirala, Krishna Babu
    Choe, Hyeonjeong
    Jeon, Byeong Uk
    Jung, Myoung Eun
    Go, Areum
    Lim, Byungho
    Park, Chaewon
    Yoon, Jiyeun
    Chae, Chong Hak
    Cho, Byoung Chul
    Choi, Gildon
    Lee, Kwangho
    BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2019, 40 (12) : 1222 - 1225
  • [3] TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
    Udagawa, Hibiki
    Hasako, Shinichi
    Ohashi, Akihiro
    Fujioka, Rumi
    Hakozaki, Yumi
    Shibuya, Mikiko
    Abe, Naomi
    Komori, Toshiharu
    Haruma, Tomonori
    Terasaka, Miki
    Fujita, Ryoto
    Hashimoto, Akihiro
    Funabashi, Kaoru
    Yasuda, Hiroyuki
    Miyadera, Kazutaka
    Goto, Koichi
    Costa, Daniel B.
    Kobayashi, Susumu S.
    MOLECULAR CANCER RESEARCH, 2019, 17 (11) : 2233 - 2243
  • [4] Discovery of a third-generation EGFR inhibitor, which is highly selective and potent against both resistant and activating EGFR mutations for NSCLC therapy
    Bao, Rudi
    Gao, Peng
    Zhang, Fujun
    Tong, Zhaolong
    Yu, Hongping
    Xu, Yaochang
    CANCER RESEARCH, 2016, 76
  • [5] Phase I study of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, showing activity in tumours with mutated EGFR
    Plummer, R.
    Vidal, L.
    Li, L.
    Shaw, H.
    Perrett, R.
    Shahidi, M.
    Amelsberg, A.
    Temple, G.
    Calvert, H.
    de Bono, J.
    EJC SUPPLEMENTS, 2006, 4 (12): : 173 - 174
  • [6] ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, demonstrates best-in-class properties against Exon 20 insertions and other atypical EGFR mutations
    Junttila, M.
    Repellin, C. E.
    Warne, R.
    Long, J. E.
    Sambucetti, L.
    Ashley, P.
    Andreatta, G.
    Baik, J.
    Salaniwal, S.
    Colas, C.
    Romero, A.
    Soroceanu, L.
    Patel, R.
    Maneval, E. Chow
    Multani, P. S.
    Daemen, A.
    Friedman, L.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S28 - S28
  • [7] Activity of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer (NSCLC) with mutated EGFR
    Spicer, James
    Calvert, Hilary
    Vidal, Laura
    Azribi, Fathi
    Perrett, Rebecca
    Shahidi, Mehdi
    Temple, Graham
    Futreal, Andrew
    De Bono, Johann
    Plummer, Ruth
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S410 - S410
  • [8] PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
    Engelman, Jeffrey A.
    Zejnullahu, Kreshnik
    Gale, Christopher-Michael
    Lifshits, Eugene
    Gonzales, Andrea J.
    Shimamura, Takeshi
    Zhao, Feng
    Vincent, Patrick W.
    Naumov, George N.
    Bradner, James E.
    Althaus, Irene W.
    Gandhi, Leena
    Shapiro, Geoffrey I.
    Nelson, James M.
    Heymach, John V.
    Meyerson, Matthew
    Wong, Kwok-Kin
    Janne, Pasi A.
    CANCER RESEARCH, 2007, 67 (24) : 11924 - 11932
  • [9] Activity of BIBW 2992, an irreversible inhibitor of EGFR and HER2, in adenocarcinoma of the lung with HER2neu kinase domain mutations
    De Greve, J.
    Teugels, E.
    Geers, C.
    De Mey, J.
    in'tveld, P.
    Decoster, L.
    Taton, M.
    Shahidi, M.
    Galdermans, D.
    Schallier, D.
    EJC SUPPLEMENTS, 2009, 7 (02): : 555 - 556
  • [10] TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X
    Ito, Kimihiro
    Nishio, Makoto
    Kato, Masanori
    Murakami, Haruyasu
    Aoyagi, Yoshimi
    Ohe, Yuichiro
    Okayama, Takashige
    Hashimoto, Akihiro
    Ohsawa, Hirokazu
    Tanaka, Gotaro
    Nonoshita, Katsumasa
    Ito, Satoru
    Matsuo, Kenichi
    Miyadera, Kazutaka
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (05) : 920 - 928
123